✦ LIBER ✦

323: Day 30 post-transplant absolute lymphocyte and natural killer cell count strongly predict outcome after allogeneic stem cell transplantation for hematological malignancy

✍ Scribed by B.N. Savani; S. Mielke; K. Rezvani; A. Yong; A. Shenoy; E.J. Read; N. Hensel; R. Childs; A.J. Barrett

Book ID: 116279503
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 64 KB
Volume: 13
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2006.12.328

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Absolute Lymphocyte Count on Day 30 Is a

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem Cell Transplantation

✍ Bipin N. Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S. Yon 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 348 KB

269: Correlates and outcome of absolute

269: Correlates and outcome of absolute lymphocyte count (ALC) on day 30 post allogeneic stem cell transplantation (SCT) for treatment of AML

✍ R.M. Saliba; K. Komanduri; S. Giralt; J. de Souza; P.A. Patah; B. Oran; G. Rondo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Non-CD34+ Cells, Especially CD8+ Cytotox

Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation Outcomes in Patients with Hematologic Malignancies after Allogeneic Peripheral Stem Cell Transplantation

✍ Dong Hwan Kim; Dong Il Won; Nan Young Lee; Sang Kyun Sohn; Jang Soo Suh; Kyu Bo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 789 KB

Liver function tests and absolute lympho

Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

✍ Fernando Silva; José A. Pérez-Simón; Teresa Caballero Velazquez; Cristina Encina 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 705 KB

The 2009 American Society of Hematology (ASH) annual meeting introduced novel strategies for the treatment of acute leukemia. Targeted inhibitors for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) represent the future of these malignancies. Inclusion of targeted treatment t